Core Insights - The collagen market is experiencing strong consumer demand and awareness, with a current industry growth phase [1][2] - The number of registered products is increasing, but the supply is not yet fully meeting consumer demand, indicating a continued industry opportunity [1][2] - In the medium term, brands with strong product differentiation will be more competitive, relying on materials and technology [1][2] - Long-term competition will shift towards a combination of product, channel, and marketing strengths [1][2] Demand Perspective - Consumers have a strong recognition of collagen, leading to robust demand [1][2] - The aesthetic medicine injection market in China is projected to reach approximately 26.8 billion yuan in 2024, with a year-on-year growth of 26.4% [2] - The collagen product segment is expected to grow at a CAGR of 50.7% from 2024 to 2028 [2] Supply Perspective - The number of registered certificates for natural and recombinant collagen is on an upward trend, with a total of 10 certificates approved for 7 companies [3][4] - The current supply of collagen products is limited, with high prices and insufficient market penetration [2][4] - The market is expected to develop a product tier system with high (>10,000 yuan), medium (4,000-6,000 yuan), and low (500-2,000 yuan) price points to cater to diverse consumer needs [2] Product Differentiation - New products are expected to innovate around materials, indications, and concentrations, leading to differentiated pricing [4] - The majority of registered products are I-type collagen, with a focus on non-crosslinked and crosslinked types [3][4] - Future developments will likely focus on unique types and amino acid sequences, enhancing product differentiation [5] Market Dynamics - The industry is currently in a growth phase, with opportunities for companies to capture market share through innovation and strategic positioning [7] - Companies with strong R&D capabilities and marketing strategies are likely to succeed in the competitive landscape [7] - The market is anticipated to see an increase in registered products, enhancing the variety of indications and price tiers available [7]

Core Viewpoint - The technology and processes for natural collagen and recombinant collagen are continuously improving, leading to an expansion of application scenarios and an increase in the number of approved collagen products, which will enrich indications and enhance market penetration [1] Industry Summary - The number of registered certificates for natural collagen and recombinant collagen products is increasing but is still far from saturation, providing opportunities for various companies to share in the industry's growth [1] - The medical beauty market is expected to see an increase in both the number of consumers and market penetration as more collagen products are approved [1] Company Recommendations - The recombinant collagen freeze-dried fiber registration certificate is expected to be approved and launched in the first half of 2026, with recombinant collagen solutions and gels also anticipated to receive approval in 2026, potentially becoming a second growth curve for companies [1] - Companies entering the natural collagen field through acquisitions, with steady progress in the research and clinical development of related medical beauty Class III devices, are expected to gain approval in the future and become new forces in the existing medical beauty biomaterials matrix [1] - Companies with strong drug development and review experience that are simultaneously laying out natural and recombinant collagen through agency and self-research are well-positioned for growth [1]

Summary of the Conference Call for Juzi Biotechnology Company Overview - Juzi Biotechnology has recently received approval for a freeze-dried fiber preparation of water light needles, targeting facial dermal tissues, including areas around the eyes, between the eyebrows, and crow's feet. This product is expected to start contributing profits in 2026, with a growth potential of around 1 billion RMB for a single product, potentially releasing tens of millions to 100 million RMB in profits [2][6]. Industry Insights - The domestic market for recombinant collagen medical devices is primarily dominated by Jinbo Biotechnology, which holds three certificates, while Juzi Biotechnology has just obtained one. Other companies, such as Chuangjian and Lafang, are also in the application process [2][4]. - Recombinant collagen has advantages over animal-derived collagen, including price competitiveness, lower allergenic risks, and no religious restrictions, indicating a broad market potential. The medical aesthetics market is projected to reach a scale of 10 billion RMB by 2025 [2][5]. Product Development and Pipeline - Juzi Biotechnology currently has four products in the application stage, including two water light needles, a gel product targeting neck wrinkles (which has entered a fast-track review), and a cross-linked recombinant collagen gel for nasolabial folds and marionette lines [3][4]. - The newly approved product is expected to bring an incremental net profit of approximately 500 million RMB, with sales potentially reaching over 1.5 billion RMB based on the development of similar products by Jinbo Biotechnology [2][6]. Competitive Landscape - The competitive landscape for recombinant collagen medical devices is characterized by limited approved certificates, with Jinbo Biotechnology leading the market. Juzi Biotechnology aims to quickly capture market share and achieve performance growth through a distribution model, while being cautious about price control [4][8]. - The technology behind recombinant collagen overcomes the limitations of extraction from animal sources, providing greater application prospects and growth potential in the medical aesthetics market [7]. Future Directions and Challenges - Juzi Biotechnology's future direction includes advancing other medical devices in the application process and rapidly capturing market share for performance growth. The company may adopt a distribution model to accelerate market penetration but must manage price control effectively [8]. - The company also faces challenges in restoring its cosmetics business due to public sentiment issues. Given the current limited number of certificates and high industry attractiveness, Juzi Biotechnology is expected to maintain a favorable competitive position in the next couple of years, while anticipating more companies entering the field to drive industry development [8].

Summary of Jinbo Biological Conference Call Company Overview - Jinbo Biological specializes in recombinant type III collagen freeze-dried fibers, which is the first injectable humanized collagen medical material on the market, marking a significant milestone in the industry [2][3] Key Points Industry and Market Dynamics - The medical health application of recombinant collagen accounts for nearly 50% of its usage, with the aesthetic medicine penetration rate continuously increasing [2] - The light aesthetic medicine injection market is expected to reach approximately 80 billion yuan by 2024, with collagen accounting for over 8 billion yuan [2][7] Product Innovation and Development - Jinbo Biological has successfully launched a micro-aesthetic collagen freeze-dried fiber product, driving high growth in overall performance [3] - The company has diversified its product forms, achieving approval for type III collagen solutions in 2023 and gel forms in 2025 [3] - The new gel product, approved in 2025, features a hexagonal structure that enhances cell adhesion and promotes tissue regeneration, with over 75% retention of new collagen [17] Competitive Advantages - Jinbo Biological is the only approved recombinant collagen class III medical device company, benefiting from the growth phase of this niche market [3] - The recombinant collagen produced through genetic engineering has significant advantages over traditional animal-derived extraction methods, including reduced immunogenicity and higher production efficiency [6] Financial Performance and Projections - The company maintains a research and development expense ratio above 10%, higher than comparable peers, facilitating rapid commercialization of research outcomes [4][11] - Revenue growth is projected at 44%, 32%, and 28% for 2025-2027, with net profit growth expected to be around 50% during the same period [20] Management and Operational Efficiency - The company has a concentrated shareholding structure, with the controlling shareholder holding 58.89%, which aids in maintaining decision-making efficiency during high growth periods [5] - Jinbo Biological employs a specialized management approach through subsidiaries, enhancing overall operational efficiency [5] International Expansion - The company has made strides in internationalization, obtaining patents in Vietnam and Brazil, and securing registration in the US and Saudi Arabia [16] Market Strategy - The new gel product is branded as "重元" (Chongyuan) to differentiate from the micro-aesthetic line, with a limited number of partnerships to maintain exclusivity [18] - The company is also expanding its functional skincare product line, which has seen rapid growth despite being in a competitive market [19] Risks and Challenges - The traditional animal-derived collagen injection market faces growth limitations due to low material acquisition efficiency and high allergenic rates [13] Additional Insights - Jinbo Biological's focus on research collaboration with universities and medical institutions enhances its innovation capabilities and accelerates the commercialization of new products [11] - The company is exploring applications in gynecology, surgery, and urology, with gynecology identified as a high-growth potential area [18]